The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study
Clinical Infectious Diseases — Bartlett SR, Wong S, Yu A, et al. | June 16, 2021
Researchers examined how current opioid agonist therapy (OAT) is associated with hepatitis C virus (HCV) treatment initiation among people who use drugs (PWUD) in a population-level linked administrative dataset. They included 13,803 PWUD with chronic HCV in this study. Among those currently on OAT at the end of the study period, 47% (2,704/5,770) had initiated HCV treatment, whereas there were 22% (1,778/8,033) of those not currently on OAT who had initiated HCV treatment. Overall findings revealed correlation of current OAT with a higher likelihood of HCV treatment initiation. However, there are many PWUD with HCV currently receiving OAT, who are yet to receive HCV treatment. They suggest the necessity for enhanced integration between substance use care and HCV treatment to improve the overall health of PWUD.